Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of
life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic
cardiomyopathy.